DEF 14A: TC BioPharm Seeks Shareholder Approval for Potential Non-Public Offerings at Upcoming AGM

TC BioPharm (Holdings) plc is convening its 2024 Annual General Meeting (AGM) on July 1, 2024, seeking shareholder approval for several resolutions, including the potential issuance of securities in non-public offerings to raise capital.

Summary

• TC BioPharm (Holdings) plc will hold its Annual General Meeting (AGM) on July 1, 2024, in Motherwell, Scotland.
• Shareholders are being asked to vote on seven resolutions, including receiving the 2023 U.K. Annual Report, approving the Directors Remuneration Report, and ratifying the appointment of auditors.
• A key resolution seeks authorization for the company to issue securities in one or more non-public offerings, potentially up to 30 million ADSs and $30 million in proceeds, to fund operations and enhance capitalization.
• The board of directors unanimously recommends that shareholders vote in favor of all resolutions.
• The company is holding the AGM as a physical meeting and encourages shareholders to submit their votes by proxy.
• A quorum of at least 33 13 percent of the issued shares entitled to vote is required to comply with Nasdaq rules.
• ADS holders can vote through The Bank of New York Mellon, the depositary bank.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. While it highlights the need for additional capital, it also emphasizes the board's confidence in the company's direction and the potential for future growth. The potential dilution of shares is a concern, but the overall tone is one of proactive management and strategic planning.

Positives

• The board of directors is actively seeking shareholder input and approval for key strategic decisions.
• The company is transparently disclosing its need for additional capital and its plans for potential non-public offerings.
• The board unanimously recommends voting in favor of all resolutions, indicating confidence in the company's direction.
• The company is providing multiple avenues for shareholders to vote, including proxy forms and electronic options.

Negatives

• The company needs to raise additional capital, indicating potential financial strain.
• The potential issuance of new securities could dilute existing shareholders' ownership.
• Failure to obtain shareholder approval for the non-public offering proposal could negatively impact the company's ability to fund operations.
• The AGM is a physical meeting, which may limit participation for some shareholders.

Risks

• The company's need for additional capital suggests potential financial instability.
• The potential non-public offerings could dilute existing shareholders' ownership and voting power.
• Failure to secure shareholder approval for the non-public offering proposal could severely limit the company's financial flexibility.
• The company's reliance on Nasdaq compliance and shareholder approval for capital raising introduces regulatory and market risks.

Future Outlook

The company intends to use the net proceeds from any potential non-public offerings to further its clinical trial program and for general corporate purposes.

Management Comments

• Your Board consider that the proposed resolutions in the Notice of AGM are in the best interests of the Company and its shareholders as a whole and are most likely to promote the success of the Company.
• Accordingly, your Board unanimously recommend that shareholders vote in favour of the resolutions.

Industry Context

Many biotech companies, especially those in the clinical trial phase, often require additional capital to fund research and development. Seeking shareholder approval for potential offerings is a common practice to maintain flexibility in accessing capital markets.

Comparison to Industry Standards

• The need for additional capital is common among clinical-stage biotech companies.
• Similar companies like Adaptimmune Therapeutics and Cellectis have also conducted public and private offerings to fund their research and development activities.
• The proposed offering size of up to $30 million is relatively small compared to larger biotech firms but is typical for companies of TC BioPharm's size and stage.

Stakeholder Impact

• Shareholders may experience dilution of their ownership if the non-public offering is approved and executed.
• Employees' job security and compensation may be affected by the company's financial performance and ability to fund operations.
• Customers may benefit from the company's ability to continue developing and commercializing its products.
• Suppliers and creditors may be impacted by the company's financial stability and ability to meet its obligations.

Next Steps

• Shareholders need to vote on the resolutions by the specified deadlines.
• The company will hold the AGM on July 1, 2024.
• The company will announce the voting results and file a Current Report on Form 8-K with the SEC.

Key Dates

Keywords

AGM, shareholder, proxy, TC BioPharm, non-public offering, ADS, capital raise, resolutions, auditor, remuneration